Sarepta Therapeutics stock holds steady as TD Cowen reiterates $17 target

Sarepta Therapeutics (SRPT) reported a significant Q2 earnings beat and resumed ELEVIDYS shipments for ambulatory patients, prompting some analyst upgrades despite its stock's over 85% decline in the past year. The company disclosed detailed liver adverse event data for ELEVIDYS, confirming an upcoming black box warning for acute liver injury, and expects initial sirolimus pre-treatment data by H1 2026 to potentially mitigate these risks. While maintaining strong liquidity, SRPT is burning cash, and analyst ratings remain mixed, reflecting both recent operational improvements and persistent safety concerns for its key Duchenne muscular dystrophy therapy.

Analysis

Sarepta Therapeutics (SRPT) presents a complex investment profile, characterized by a significant second-quarter earnings beat and positive operational updates clashing with material safety concerns for its key Duchenne muscular dystrophy (DMD) therapy, Elevidys. The company reported adjusted earnings of $2.02 per share against a $0.70 consensus and revenue of $611.1 million, a 68% year-over-year increase, far exceeding the $532.86 million forecast. This financial outperformance, coupled with the resumption of ELEVIDYS shipments, has prompted analyst upgrades, including a move to Buy from Freedom Broker and a price target increase to $50 from Wells Fargo. However, a significant headwind remains in the form of an upcoming black box warning for acute liver injury (ALI) on the Elevidys label, a risk confirmed for both ambulatory and non-ambulatory patients. While the company has strong liquidity with a current ratio of 2.89, it is also reportedly burning through cash. A potential mitigating therapy, sirolimus pre-treatment, will not have initial data available until the first half of 2026, creating a prolonged period of uncertainty that is reflected in the stock's 85% decline over the past year and the wide dispersion of analyst price targets.

Key Decisions for Investors

• Investors should weigh the strong Q2 financial outperformance and resumed ELEVIDYS shipments against the significant, formalized risk of an upcoming black box warning for liver injury.
• The H1 2026 timeline for initial data on sirolimus as a potential mitigator for liver side effects creates a long-term catalyst to monitor, but implies the safety overhang will persist for the medium term.
• Given the stock's 85% decline and the wide range of analyst price targets, positions in SRPT are subject to high volatility, requiring a careful assessment of risk tolerance.
• Despite a strong liquidity ratio of 2.89, the company's cash burn rate should be closely monitored as a key financial risk until the commercial and safety profile of Elevidys is fully established.